ZVSAOTCPharmaceutical PreparationsFiscal year ends December 31

ZyVersa Therapeutics, Inc.

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 13, 2026

$0.05+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $388.60K
P/E (TTM): –
Dividend yield: –

ZyVersa Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research & Development	1.11	1.78	3.21
General & Administrative	5.73	7.36	11
Operating Expenses	25	9.14	108
Operating Income	-25	-9.14	-108
Asset Impairment Charges	19	0	12
Pretax Income	-26	-9.41	-108
Income Tax Expense	-0.85	0.01	-9.46
Net Income	-25	-9.41	-98
Preferred Dividends	–	–	7.95
Net Income to Common	–	-9.41	-106
EPS (Basic)(per share)	-4.18	-8.48	-1,089.70
EPS (Diluted)(per share)	-4.18	-8.48	-1,089.70
Shares Outstanding (Basic, Weighted)(shares)	5.96	1.11	0.10
Shares Outstanding (Diluted, Weighted)(shares)	5.96	1.11	0.10
Net Interest Income	-0.51	-0.27	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 1289.4%

Financial strength

Current ratio: 0.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –